BioPharmSignal logoBioPharmSignal

Biotech News

Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Assembly Biosciences (ASMB)Assembly BiosciencesFinancing

SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced the closing of its previously announced underwritten registered offering of

Related news

ASMBAssembly Biosciences2026-05-22 11:05 EST

Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

ASMBAssembly Biosciences2026-10-05 14:00 EST

Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026

MBRXMoleculin Biotech, Inc.2026-07-31 14:12 EST

Moleculin Announces Pricing of $9.3 Million Public Offering

SPROSpero Therapeutics2026-07-14 11:02 EST

Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties

IMNNImunon2026-06-04 12:00 EST

IMUNON Announces Up to $10 Million Cash Financing

VIRIVirios Therapeutics2026-10-19 12:30 EST

Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc.

COCPCocrystal Pharma2026-08-03 11:00 EST

Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health

ABUSArbutus2026-08-24 11:30 EST

Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share

ABUSArbutus2026-08-21 11:30 EST

Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer

ANTXAN2 Therapeutics2026-08-31 22:00 EST

AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

View all latest news

Assembly Biosciences

Antiviral Small Molecules Assembly Biosciences develops oral small-molecule therapies for serious viral diseases. Its portfolio targets viral replication mechanisms with the goal of improving suppression or enabling finite treatment. Recurrent Genital Herpes ABI-5366 and ABI-1179 are helicase-primase inhibitors that have completed Phase...

Recent company news

ASMBAssembly Biosciences2026-11-02 21:00 EST

Assembly Biosciences to Participate in Upcoming Investor Conferences

ASMBAssembly Biosciences2026-10-29 20:00 EST

Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus

ASMBAssembly Biosciences2026-10-05 14:00 EST

Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026

ASMBAssembly Biosciences2026-09-10 20:15 EST

Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference

ASMBAssembly Biosciences2026-09-08 20:00 EST

Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program

Stock data

Close
20.00 USD
Market cap
485.32M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States